Protalix ( ($PLX) ) has issued an update. On November 3, 2025, Protalix BioTherapeutics and Chiesi Global Rare Diseases announced their request ...

A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If ...

Researchers have gained new insights into the genetic basis of rye reproduction. They have demonstrated how plants recombine ...

A research team led by Prof. Hou Xingliang from the South China Botanical Garden of the Chinese Academy of Sciences has used ...

production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system," issued a press release on October 17, 2025, ...

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based ...

The collaboration between the University and CyanoCapture will focus on developing innovative methods for producing targeted delivery systems using engineered carboxysomes, combining advanced ...

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life ...

Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw ...

Background: Acute myocardial infarction (AMI) remains the leading cause of cardiovascular-related mortality worldwide, with inflammation significantly influencing its progression and prognosis.

Politecnico di Milano, Department of Chemistry, Materials and Chemical Engineering “G. Natta”, Via Mancinelli 7, 20131 Milano, Italy ...